StockNews.AI
INSP
StockNews.AI
13 days

Inspire Medical Systems, Inc. Investors: Company Investigated by the Portnoy Law Firm

1. Investors face potential losses from Inspire Medical due to securities fraud investigation. 2. Inspire revised its revenue guidance down to $900 million-$910 million for 2025. 3. Company's diluted net income per share is now forecasted at $0.40 to $0.50. 4. Stock price plummeted by 32.35% after the disappointing financial results were announced. 5. Law firm encourages affected investors to pursue legal claims for recovery.

4m saved
Insight
Article

FAQ

Why Very Bearish?

The significant drop in revenue guidance and its association with potential fraud typically leads to considerable investor panic, mirroring patterns in similar cases with sharp post-announcement declines, indicating deep loss of trust and confidence in the Company.

How important is it?

The article directly addresses significant financial revisions and potential fraud, immediate investor sentiment drops, leading to high relevance and importance for current and prospective investors in INSP.

Why Short Term?

The immediate response to financial disclosures typically affects stock prices rapidly; historical instances, like those of Enron, illustrate short-term impacts due to market reactions to credibility concerns.

Related Companies

INSP
Investors can contact the law firm at no cost to learn more about recovering their losses ​LOS ANGELES, Aug. 06, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Inspire Medical Systems, Inc. (“Inspire Medical” or “the Company”) (NYSE: INSP) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors. Inspire Medical investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: info@portnoylaw.com, to discuss their legal rights, or click here to join the case. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses. On August 4, 2025, Inspire issued a press release announcing its financial results for the second quarter of 2025 and provided an updated outlook for the remainder of the year. Among other disclosures, the Company revised its full-year revenue guidance downward to a range of $900 million to $910 million and reduced its expected diluted net income per share to $0.40 to $0.50. This represented a significant decrease from its prior guidance of $940 million to $955 million in revenue and $2.20 to $2.30 in diluted net income per share. Inspire attributed the revised outlook to slower-than-expected progress in the commercial launch of its next-generation Inspire V neurostimulation system. Following the announcement, Inspire’s stock price declined $42.04 per share, or approximately 32.35%, closing at $87.91 per share on August 5, 2025. Please visit our website to review more information and submit your transaction information. The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes. Lesley F. Portnoy, Esq.Admitted CA, NY and TX Barslesley@portnoylaw.com310-692-8883www.portnoylaw.com Attorney Advertising

Related News